Fenwick Represents Cadence Neuroscience in $26 Million Series B Financing

Fenwick represented Cadence Neuroscience, a medical device company developing new therapies for the treatment of epilepsy and other neurological disorders, in its $26 million Series B financing. The round was led by Angelini Lumira Biosciences Fund and included other new investors F-Prime Capital, LivaNova USA, Angelini Ventures, Spectrum Financial Services and Mayo Clinic, as well as the company's Series A lead investor JAZZ Venture Partners.

The company will use the Series B funds to complete pivotal clinical studies and pursue FDA clearance. More information can be obtained from the company's announcement.

The Fenwick transaction team was led by corporate partner Alan C. Smith and included corporate partner Katherine K. Duncan and corporate associates Annie Omata, David Heckman, Patrick White and Jillian Victor.